Instrument Inactif

Autres langues Pieris Pharmaceuticals

Actions

PIRS

US7207952026

Autres langues

16/12/24	Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
16/12/24	Pieris Pharmaceuticals : Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million Form 8 K
13/12/24	Palvella Therapeutics, Inc.(NasdaqCM:PIRS) dropped from NASDAQ Composite Index
13/12/24	Palvella Therapeutics, Inc. completed the acquisition of Pieris Pharmaceuticals, Inc. in a reverse merger transaction.
20/11/24	PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
13/11/24	Pieris Pharmaceuticals: Q3 Earnings Snapshot
13/11/24	Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
07/11/24	Pieris Pharmaceuticals' Merger Target Palvella Doses First Patient in Phase 3 Trial of Lymphatic Drug
07/11/24	Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
17/10/24	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
16/10/24	Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance Annual Conference
03/10/24	Pieris Pharmaceuticals : Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single Arm, Baseline Controlled Trial in Microcystic Lymphatic Malformations Form 8 K
15/08/24	Pieris Pharmaceuticals: Q2 Earnings Snapshot
14/08/24	Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
07/08/24	Pieris Pharmaceuticals, Inc. announced that it has received funding
25/07/24	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
25/07/24	Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment
25/07/24	PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
24/07/24	Top Midday Gainers
24/07/24	Pieris Pharmaceuticals, Palvella Therapeutics Agree to Merge; Pieris Shares Jump
24/07/24	Traders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity Futures
24/07/24	Top Premarket Gainers
24/07/24	Pieris Pharmaceuticals, Inc. Announces Stepping Down of Shane Olwill as Senior Vice President and Chief Development Officer
24/07/24	Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. Announce Definitive Merger Agreement
24/07/24	Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. in a reverse merger transaction.